30
Participants
Start Date
December 11, 2024
Primary Completion Date
November 1, 2025
Study Completion Date
April 1, 2026
Ropivacaine 0,1%
"The study uses ropivacaine for nerve blocks, starting at 0.1% concentration and capped at 0.5% for safety. Concentration adjustments are made based on each participant's response 60 minutes post-injection:~* Increase by 0.025% if pain reduction is \<50%~* Increase by 0.025% if reduction is 50-75% without sensory/motor block~* Decrease by 0.025% if reduction is 50-75% with sensory/motor block~* Decrease by 0.025% if reduction is \>75%. Pain is assessed using a Numerical Rating Scale. The study employs Dixon's up-and-down method for five cycles to determine the optimal concentration for effective pain relief without significant numbness or weakness."
NaCl (placebo)
0.9 % NaCl solution (saline) injection
NOT_YET_RECRUITING
Balgrist University Hospital, Zurich
RECRUITING
Balgrist University Hospital, Zurich
Balgrist University Hospital
OTHER